Drotrecogin Alfa (Activated): A Viewpoint by Marcel Levi

Levi, M.
February 2002
Drugs;2002, Vol. 62 Issue 4, p631
Academic Journal
Examines the therapeutic use of protein C in the treatment of sepsis. Role of microvascular thrombosis in organ failure and mortality in patients with sepsis; Beneficial effect of activated protein C; Strategies to reduce mortality from sepsis.


Related Articles

  • World's Largest Severe Sepsis Clinical Trial.  // BioPharm International;Nov2002, Vol. 15 Issue 11, p14 

    Reports on the approval received by Eli Lilly's drug Xigris, a recombinant form of human protein C, by the U.S. Food and Drug Administration for reducing mortality in severe sepsis adults at high risk of death. Launch of a severe sepsis clinical trial which will study the effectiveness of...

  • Lilly Hopes Sepsis Drug Will Cushion Prozac Expiry. Jarvis, Lisa // Chemical Market Reporter;11/27/2000, Vol. 258 Issue 22, p5 

    Reports on the development of a recombinant human activated protein C drug for the treatment of sepsis, manufactured by Eli Lilly & Co. Estimated number of people in the United States who suffered from sepsis annually; Benefits given by the drug to the company.

  • Treatment of sepsis with activated protein C. Hinds, C J // BMJ: British Medical Journal (International Edition);10/20/2001, Vol. 323 Issue 7318, p881 

    Editorial. Discusses the possible treatment of severe sepsis using a continuous intravenous infusion of recombinant human activated protein C. Past difficulty finding a treatment for the inflammatory response related to severe sepsis; Mortality from severe sepsis; Theory of why protein C is...

  • The Pathophysiology and Treatment of Sepsis. Hotchkiss, Richard S.; Karl, Irene E. // New England Journal of Medicine;1/9/2003, Vol. 348 Issue 2, p138 

    Reports on the pathophysiology and treatment of sepsis. How sepsis is the leading cause of death in critically ill patients; View that new therapies have been developed to treat sepsis; View that sepsis represents an uncontrolled inflammatory response; Suggestion that sepsis is consistent with...

  • Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis. Bernard, Gordon R.; Vincent, Jean-Louis; Laterre, Pierre-Francois; LaRosa, Steven P.; Dhainaut, Jean-Francois; Lopez-Rodriguez, Angel; Steingrub, Jay S.; Garber, Gary E.; Helterbrand, Jeffrey D.; Ely, E. Wesley; Fisher, Charles J. // New England Journal of Medicine;03/08/2001, Vol. 344 Issue 10, p699 

    Background: Drotrecogin alfa (activated), or recombinant human activated protein C, has antithrombotic, antiinflammatory, and profibrinolytic properties. In a previous study, drotrecogin alfa activated produced dose-dependent reductions in the levels of markers of coagulation and inflammation in...

  • An Economic Evaluation of Activated Protein C Treatment for Severe Sepsis. Manns, Braden J.; Lee, Helen; Doig, Christopher James; Johnson, David; Donaldson, Cam // New England Journal of Medicine;9/26/2002, Vol. 347 Issue 13, p993 

    Background: Recombinant human activated protein C was shown in the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study to reduce mortality among patients with severe sepsis. A post hoc reanalysis by the Food and Drug Administration (FDA) of data from this...

  • Risks and Benefits of Activated Protein C Treatment for Severe Sepsis. Warren, H. Shaw; Suffredini, Anthony F.; Eichacker, Peter Q.; Munford, Robert S. // New England Journal of Medicine;9/26/2002, Vol. 347 Issue 13, p1027 

    Discusses the risks and benefits of activated protein C treatment for severe sepsis. The two phases of the activated protein C trial; Subgroups and restrictions to use in high-risk patients; The risk of serious hemorrhage; The conclusion that activated C is effective with some patients.

  • Assessing the Use of Activated Protein C in the Treatment of Severe Sepsis. Siegel, Jay P. // New England Journal of Medicine;9/26/2002, Vol. 347 Issue 13, p1030 

    Assesses the use of activated protein C in the treatment of severe sepsis. Patients with serious preexisting diseases; Use of the APACHE II score; Risk of bleeding and survival benefits; The conclusion that the correct use of protein C will save lives.

  • Eli Lilly's Xigris Approved. Krause, Carey // Chemical Market Reporter;12/03/2001, Vol. 260 Issue 21, p12 

    Reports that Eli Lilly and Co. has received Food & Drug Approval for Xigris, a recombinant human activated protein C to treat severe sepsis. Retail price of the drug; Estimation on the market value of Xigris by 2002 and 2005.


Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics